Your Cart (0)
Your cart is empty
Taxes included. Shipping and discounts are calculated at checkout.
SAVE 20% WITH CODE NEU20 UNTIL 26 JULY・FREE JAR OF LAMBDA PLUS ON ORDERS OVER €100
SAVE 20% WITH CODE NEU20 UNTIL 26 JULY・FREE JAR OF LAMBDA PLUS ON ORDERS OVER €100
Drawer menu
Taxes included. Shipping and discounts are calculated at checkout.
Subtotal: CHF 0.00
Inhaltsstoff-Glossar
Several cross-sectional studies and randomized controlled trials (RCTs) have shown that vitamin K status or supplementation can improve certain markers of bone health. In particular, low vitamin K intake appeared to be associated with bone loss in female participants. Overall, however, the available evidence is inconsistent, and the level of scientific evidence remains limited.
In a meta-analysis of nine randomized controlled trials conducted by a Canadian research group investigating the effects of vitamin K supplementation on arterial calcification and vascular damage, vitamin K increased the activity of an enzyme that helps prevent calcium deposition within blood vessels. However, the authors found no strong evidence that vitamin K supplementation effectively prevents or treats atherosclerosis. Further research is needed to determine whether vitamin K can prevent vascular calcification or improve existing atherosclerotic disease.
Like vitamin K, vitamin D is an essential nutrient for bone health. Studies have demonstrated that combining both vitamins in a single supplement enhances their beneficial effects on bone mineral density. Particularly in individuals with a high calcium intake—as is common in Western societies—the combination may help protect against calcium deposits that could develop as a result of excessive vitamin D intake.
Because there is currently no reliable biomarker for assessing the body's vitamin K status, nor sufficiently reliable data on the vitamin K content of foods, the German Federal Institute for Risk Assessment (BfR) classifies vitamin K as a Category 2 nutrient. According to the BfR, there is a certain degree of uncertainty regarding vitamin K supply and the potential development of deficiency.
If dietary intake is insufficient to meet vitamin K requirements, pharmacy-grade oral supplements providing 50–150 micrograms per day are available. In cases of life-threatening bleeding, up to 10 mg of vitamin K may be administered intravenously. Risk groups for vitamin K deficiency include individuals with eating disorders, inflammatory bowel diseases such as Crohn's disease, patients taking medications that interfere with the vitamin K cycle (including coumarin derivatives and certain antibiotics), as well as newborns and infants.
The BfR considers the risk of vitamin K overdose to be moderate and the risk of adverse effects to be low. Toxic reactions such as allergic responses or cardiac arrhythmias have been observed only rarely and primarily after intravenous administration of large doses. For individuals taking anticoagulant medications, the BfR considers a daily vitamin K intake of up to 100 micrograms to be safe. Higher intakes may result in life-threatening complications and should only be taken under medical supervision.
Further information and scientific studies on the active ingredient vitamin K can be found here.
Vitamin K and Osteoporosis: Myth or Reality?
pubmed.ncbi.nlm.nih.gov/28403946
LONGEVITY CLUB
The Longevity Club is neotes’ personal guidance circle for people who want to shape their health with foresight. A few short questions help us understand where you stand and how we can support you best.